ResMed: Digital Health Drives Q2 Growth
(NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion.
The great quarter was driven by high demand for sleep-related products and growth in digital health solutions.
Source: ResMed. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
Source Fool.com
Resmed Inc. Stock
€222.10
-0.530%
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 259 € shows a slightly positive potential of 16.61% compared to the current price of 222.1 € for Resmed Inc..
